Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Vertex Pharmaceuticals announced that it will be discontinuing the sale and distribution of Incivek (telaprevir) tablets in the United States by October 16, 2014.
Incivek is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of genotype 1 infection, in combination with peginterferon alfa and ribavirin in patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based therapy, including prior null responders, partial responders, and relapsers.
The decision to discontinue Incivek was based on alternative treatments that are currently available and the decreasing market demand for Incivek.
RELATED: Recommendations for the Treatment of Hepatitis C Virus
Healthcare providers are requested to not start any new patients on Incivek treatment. Vertex will continue to provide financial support to those who are currently prescribed Incivek and will address available drug supply needs to complete therapy.
For more information call (877) 824-4281 or visit Incivek.com.
